Efficacy and safety of first-line Vinorelbine single agent in patints with refractory to anthracycline and taxane

Efficacy and safety of first-line Vinorelbine single agent in patints with refractory to anthracycline and taxane - Efficacy and safety of first-line Vinorelbine single agent

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000572

Enrollment

Registered

2007-01-10

Start date

2006-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

First-line metastatic breast cancer

Interventions

vinorelbine

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) First-line metastatic breast cancer 2) had adjuvant chemotherapy with anthracycline and taxane 3) negative for HER2/neu 4) PS0-2 (ECOG) 5) having measureable lesion according to RECIST 6) survival longer than 3 months 7) having adequete organ function 8) obtained written informed consent

Exclusion criteria

Exclusion criteria: 1) had another chemotherapy after recurrence 2) having active multiple cancers 3) having serious infenction or severe organ function

Design outcomes

Primary

Measure	Time frame
Time to progression	—

Secondary

Measure	Time frame
Response rate, toxicity	—

Countries

Japan

Contacts

Public ContactMasataka Sawaki

Nagoya University school of medicine Department of Breast and Endocrine surgery

sawapi@qc4.so-net.ne.jp052-744-2251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026